Abstract
Objective To explore the clinical features of electric ophthalmia and the therapeutic effect of recombinant human epidermal growth factor (rhEGF) eye drops. Methods 86 cases of electric ophthalmia were randomly divided into the treatment group and the control group with 43 cases in each group. The treatment group was treated with rhEGF eye drops combined with dicaine, while the control group was treated with erythromycin ointment combined with dicaine. The clinical features including gender, age, nosogenesis, and clinical manifestations of 86 patients were analyzed, and the curative effect and disappearance time of clinical symptoms were compared between the two groups. Results the majority of patients with electric ophthalmia were men under the age of 40 years old, mostly caused by welding light burn, and the common clinical manifestations were conjunctival congestion and edema, severe eye pain, photophobia and so on. The total effective rate in the treatment group was higher than that in the control group (95.35% vs.81.40%) (P<0.05), and the disappearance times of conjunctival congestion, eyelid edema, pain, and photophobia in the treatment group were shorter than those in the control group [(5.23±1.14)h vs.(6.85±1.26)h, (6.37±1.28)h vs.(7.46±1.35)h, (10.58±2.03)h vs.(12.36±2.17)h, (12.42±2.35)h vs.(13.69±2.46)h] (P<0.05). Conclusions Electric ophthalmia mainly occurs in the young or middle aged men taking welding light burn as the main cause, and the common symptoms are conjunctival congestion and edema, severe eye pain, photophobia and so on. The rhEGF eye drops can effectively improve the patients' clinical symptoms, with definite and rapid efficacy. Key words: Electric ophthalmia; Recombinant human epidermal growth factor; Dicaine; Erythromycin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
